Table 1.
Demographic characteristics of participants
| Demographics | HV (n = 31) | CHR (n = 25) | FEP (n = 16) | |
|---|---|---|---|---|
| Mean age ± SD (years) | 22.2 ± 3.1 | 21.0 ± 2.1 | 24.5 ± 5.8 | F(2,69) = 4.69, p = 0.012 |
| Sex (male/female) | 13/18 | 12/13 | 15/1 | X2(2,72) = 12.36, p = 0.02 |
| Cannabis use | 13 | 2 | 4 | |
| Antipsychotic use | 0 | 6 | 3 | |
| Antidepressant usea | 0 | 6 | 5 | |
| Benzodiazepine use | 0 | 3 | 1 | |
| Duration of illness (months) | – | – | 19.6 ± 26.3 | |
| RBANS total | – | 90.3 ± 13.7 | 84.5 ± 16.3 | |
| PANSS positive | – | – | 16.5 ± 4.7 | |
| PANSS negative | – | – | 12.4 ± 4.8 | |
| SOPS positive | – | 11.4 ± 3.5 | – | |
| SOPS negativeb | – | 11.2 ± 5.5 | – |
RBANS repeatable battery for the assessment of neuropsychological status, SOPS scale of psychosis-risk symptoms, PANSS positive and negative syndrome scale
aThe antidepressants were selective serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake inhibitors (SNRI) and bupropion
bSOPS negative score was unavailable for one CHR